Sphera Signs Agreement to Acquire riskmethods, a Leader in Artificial Intelligence Supply Chain Risk Management Software
13.9.2022 16:30:00 EEST | Business Wire | Press release
Sphera, a leading global provider of Environmental, Social and Governance (ESG) performance and risk management software, data and consulting services, announces it has entered into an agreement to acquire riskmethods, a Munich, Germany-based, award-winning software company specializing in supply chain risk management (SCRM).
Founded in 2013, riskmethods’ software as a service (SaaS) solution harnesses cutting-edge artificial intelligence (AI), big data and machine learning to protect its customers’ supply chain networks. Its software platform collects supplier data and real-time information, distinguishes critical signals from “noise” and provides users with detailed status of suppliers, so they can prevent business disruption risk before it materializes and achieve supply chain transparency.
“riskmethods’ cloud-based software identifies, analyzes and helps mitigate all types of supply chain risk, including monitoring sustainability practices and ESG compliance in the supply chain. Their innovative approach to SCRM bolsters Sphera’s capabilities in offering a Scope 3 emissions monitoring and reporting solution and furthers our mission of creating a safer, more sustainable and productive world,” said Paul Marushka, Sphera’s president and CEO. “And their presence in Europe and the U.S. reinforces our ability to serve our expanding global customer base.”
The company’s SCRM software solution is a robust tool for managing risk in increasingly complex supply chains, as well as handling ever-expanding regulatory compliance. With global companies operating in a world of disruption and turbulence—pandemics and climate change, to name a few—riskmethods offers real-time SCRM solutions that enable businesses to proactively manage potential supply chain risks and comply with emerging operational and ESG regulations.
“For the last 10 years, riskmethods has been empowering businesses to master supply chain risk and create reliable supply networks,” said Heiko Schwarz, riskmethods’ CEO and founder. “Adding our advanced AI and machine-learning SCRM software solution to Sphera’s product portfolio will enable us to further our reach across the globe and help even more customers manage supply chain risk. We are excited to join the Sphera family of leading ESG software, data and consulting solutions.”
Kelly Wannop, Managing Director at Blackstone, said, “Blackstone’s 2021 investment in Sphera reflected our conviction in Sphera’s ESG mission and growth. The planned acquisition of riskmethods further demonstrates our commitment to helping Sphera expand their operational ESG solutions.” Eli Nagler, a Senior Managing Director at Blackstone, continued, “We are excited to welcome riskmethods to Sphera and eager to extend their SCRM solutions to even more customers.”
ReedSmith LLP and Simpson Thatcher & Bartlett LLP served as legal advisors to Sphera and Blackstone while Evercore served as the financial advisor. For the sellers, DLA Piper served as legal advisor, and Stifel served as the financial advisor.
About Sphera
Sphera is the leading provider of Environmental, Social and Governance (ESG) performance and risk management software, data and consulting services focusing on Environment, Health, Safety & Sustainability (EHS&S), Operational Risk Management and Product Stewardship. For more than 30 years, we have served over 6,700 customers and a million-plus users in 80 countries to help companies keep their people safe, their products sustainable and their operations productive. Learn more about Sphera at www.sphera.com. Follow Sphera on LinkedIn.
About riskmethods
riskmethods enables organizations worldwide to identify, analyze and mitigate all types of supply chain risk management (SCRM). riskmethods’ software utilizes artificial intelligence (AI) and machine learning to protect its customers’ supply chain network. Its software platform collects supplier data and real-time information, distinguishes critical signals from “noise” and provides users with visibility across multiple tiers of their supply chain, so they can mitigate business disruption risk and achieve supply chain transparency. The company’s 200+ employees across 4 offices worldwide serve more than 225 enterprise customers. More information can be found at www.riskmethods.net.
About Blackstone
Blackstone is the world’s largest alternative investment firm. We seek to create positive economic impact and long-term value for our investors, the companies we invest in, and the communities in which we work. We do this by using extraordinary people and flexible capital to help companies solve problems. Our $941 billion in assets under management include investment vehicles focused on private equity, real estate, public debt and equity, infrastructure, life sciences, growth equity, opportunistic, non-investment grade credit, real assets and secondary funds, all on a global basis. Further information is available at www.blackstone.com. Follow Blackstone on Twitter @Blackstone.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220913005415/en/
Contact information
Astrid Dickinson
Aspectus Group
sphera@aspectusgroup.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
IQM Appoints Craig Ciesla, Former Illumina VP, as CTO; Inés de Vega Becomes Chief Scientist19.6.2026 10:00:00 EEST | Press release
IQM Quantum Computers, the global leader in superconducting quantum computers, today announced the appointments of Dr. Craig Ciesla as Chief Technology Officer (CTO) and Dr. Inés de Vega as Chief Scientist, as she transitions from her role as Vice President of Quantum Solutions, deepening IQM´s leadership as the company prepares for its planned Nasdaq listing through a merger with Real Asset Acquisition Corp. (Nasdaq: RAAQ). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260619693929/en/ From left to right: Dr. Inés de Vega, Chief Scientist, and Dr. Craig Ciesla, Chief Technology Officer. Ciesla, an experienced deep tech executive with more than 25 years delivering products across multiple industries from startups to Fortune 500 companies, will advance IQM's technology strategy and drive its implementation into systems and products. De Vega, meanwhile, will be responsible for ensuring scientific feasibility and system-level
Teijin Receives Approval for Additional Indications of XEOMIN ® for Cervical Dystonia and Blepharospasm in Japan19.6.2026 10:00:00 EEST | Press release
Teijin Pharma Limited, the core company of the Teijin Group’s healthcare business, and Merz Therapeutics GmbH, a leading player in neurology-focused specialty pharma, jointly announced today that Japan’s Ministry of Health, Labour and Welfare (MHLW) has approved the additional indications for XEOMIN® (incobotulinumtoxinA) for the treatment of cervical dystonia and blepharospasm. This approval represents the fourth and fifth indications for XEOMIN® authorized in Japan, alongside its existing approvals for the treatment of upper limb spasticity, lower limb spasticity and chronic sialorrhea. Cervical dystonia is a focal dystonia characterized by involuntary contractions of the neck muscles, resulting in abnormal or repetitive movements and postures.1 Blepharospasm is also a focal dystonia, characterized by excessive involuntary contractions of the muscles surrounding the eye.2 Both conditions significantly impact patients’ quality of life. The approval by MHLW is based on Phase III clinic
Incyte Japan Announces Approval of Minjuvi ® (tafasitamab) in Combination with Lenalidomide for the Treatment of Adults with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)19.6.2026 09:00:00 EEST | Press release
Incyte Biosciences Japan G.K. today announced that Japan’s Ministry of Health, Labour and Welfare (MHLW) has approved Minjuvi® (tafasitamab) in combination with lenalidomide for the treatment of adults with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). “This approval provides a new option for patients in Japan living with relapsed or refractory DLBCL, an aggressive disease with historically limited treatment options,” said Yasuyuki Ishida, General Manager, Incyte Biosciences Japan. “We are committed to helping address critical unmet needs for patients and their families affected by this challenging cancer.” DLBCL is the most common subtype of non-Hodgkin lymphoma and is an aggressive malignancy of B lymphocytes. While many patients respond to initial therapy, outcomes remain poor for those with relapsed or refractory disease, particularly for patients who are not eligible for autologous stem cell transplant.1 The approval is based on results from the MOR208C203 Trial: L
Amazfit Introduces Helio Strap Pro, Bringing Body-Worn Movement Intelligence to HYROX and Hybrid Training18.6.2026 20:07:00 EEST | Press release
Amazfit, a leading global smart wearable brand owned by Zepp Health (NYSE: ZEPP), today announced Helio Strap Pro, a body-worn training system designed to help HYROX and hybrid athletes better understand how their bodies perform under load. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260618031434/en/ Amazfit Introduces Helio Strap Pro, Bringing Body-Worn Movement Intelligence to HYROX and Hybrid Training Building on the screen-free Helio Strap, Helio Strap Pro adds a dedicated waist-mounted motion sensor that captures core-body movement and stability during training. Combined with upper-arm heart-rate sensing and compatible Amazfit smartwatches, the system provides a more complete picture of cardio effort, movement quality and muscle load than wrist-based tracking alone. Helio Strap Pro represents the next evolution of Amazfit's Hybrid Training System, extending performance tracking beyond heart rate to help athletes bett
HyperLight Announces $80 Million Series C to Accelerate TFLN Deployment for AI Infrastructure18.6.2026 18:30:00 EEST | Press release
HyperLight Corporation (“HyperLight”), a leader in thin-film lithium niobate (TFLN) photonics, today announced the closing of an $80 million Series C financing round led by MediaTek. The round includes participation from UMC Capital, Jabil, Foxconn, EDBI (arm of SG Growth Capital, the investment platform of the Singapore Economic Development Board and Enterprise Singapore), CDIB-TEN Capital, and Qatar Investment Authority (QIA), as well as strategic investors from leading silicon IC and networking companies. Existing investors Summit Partners, The Engine, Foothill Ventures, and Xora Innovation continue to actively support the company’s growth. The financing brings together companies across the AI infrastructure value chain — including silicon ICs, foundry manufacturing, electronics manufacturing services, networking, and global infrastructure investment — reflecting broad ecosystem support for scaling TFLN photonics into production. “This financing is about more than capital — it is ab
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
